CADTH | Search

Current Filters

Showing 41 - 50 results of 3579

Treanda for indolent Non-Hodgkin Lymphoma (Treanda) (Last Updated: Dec 14, 2012)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indication

Brand Name:
Treanda
Manufacturer:
Lundbeck Canada Inc.
Submission Type:
Initial

Treanda for Chronic Lymphocytic Leukemia (First Line) (Treanda) (Last Updated: Mar 6, 2013)

As per pCODR Procedures B5.4, the pERC deliberations for Bendamustine (Treanda) First Line treatment of patients with CLL were deferred to the January 17, 2013 pERC meeting date, once the submitter...

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indication

Brand Name:
Treanda
Manufacturer:
Lundbeck Canada Inc.
Submission Type:
Initial

Treanda for Chronic Lymphocytic Leukemia (Relapsed/ Refractory) (Treanda) (Last Updated: Dec 14, 2012)

As per pCODR Procedures B5.4, the pERC deliberations for Bendamustine (Treanda) First Line treatment of patients with CLL was deferred to the January 17, 2013 pERC meeting date, once the submitter...

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indication

Brand Name:
Treanda
Manufacturer:
Lundbeck Canada Inc.
Submission Type:
Initial

Tafinlar for Metastatic Melanoma - Details (Tafinlar) (Last Updated: Dec 20, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indication

Brand Name:
Tafinlar
Manufacturer:
GlaxoSmithKline
Submission Type:
Initial

Sylvant Multicentric Castleman's Disease - Details (Sylvant) (Last Updated: Jul 8, 2015)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indication

Brand Name:
Sylvant
Manufacturer:
Janssen Inc.
Submission Type:
Initial
Download results as CSV